SCI_Celine_French_celine_OT.wmv
Spinal cord injury patient during stem cell treatment at Wu stem cell medical center in Beijing.From:wustemcellcenterViews:333 1ratingsTime:00:13More inScience Technology
Originally posted here:
SCI_Celine_French_celine_OT.wmv - Video
SCI_Cartaze_USA_after2.wmv
Spinal cord injury patient after stem cell treatment at Wu stem cell medical center in Beijing.From:wustemcellcenterViews:45 0ratingsTime:01:54More inScience Technology
View post:
SCI_Cartaze_USA_after2.wmv - Video
SCI_Celine_French_moving_right_hand.wmv
Spinal cord injury patient during stem cell treatment at Wu stem cell medical center in Beijing.From:wustemcellcenterViews:50 0ratingsTime:00:11More inScience Technology
Original post:
SCI_Celine_French_moving_right_hand.wmv - Video
Stroke_Li_China_after2.wmv
Stroke/CVA patient after stem cell treatment at Wu stem cell medical center in BeijingFrom:wustemcellcenterViews:44 0ratingsTime:00:55More inScience Technology
The rest is here:
Stroke_Li_China_after2.wmv - Video
Stem_Cell_Therapy_for_ALS.wmv
Amel is 58 and has been diagnosed with ALS and Progressive Bullbar Palsy (PBP). She can not be treated by conventional western medicine so Amel #39;s family sent her to Wu Stem Cell Medical Center for Stem Cell Treatment. After treatment at WSCMC, Amel can now talk more clearly and has more control over her tongue making eating easier. She has felt the improvements and is noticeably happier. Read the full story here..... http://www.wustemcells.web.idFrom:WSCMCindonesiaViews:52 0ratingsTime:01:23More inScience Technology
Read the original:
Stem_Cell_Therapy_for_ALS.wmv - Video
Wu stem cell medical center hospital introduction video.avi
Visit us at http://www.unistemcells.com for more information on stem cell treatment in Beijing, China. You can also email us at wu@unistemcells.com or randyrobinson.china@gmail.comFrom:wustemcellcenterViews:412 1ratingsTime:06:42More inScience Technology
Go here to see the original:
Wu stem cell medical center hospital introduction video.avi - Video
Newswise WINSTON-SALEM, N.C. Oct. 12, 2012 Scientists at Wake Forest Baptist Medical Center have taken the first steps to create neural-like stem cells from muscle tissue in animals. Details of the work are published in two complementary studies published in the September online issues of the journals Experimental Cell Research and Stem Cell Research.
Reversing brain degeneration and trauma lesions will depend on cell therapy, but we cant harvest neural stem cells from the brain or spinal cord without harming the donor, said Osvaldo Delbono, M.D., Ph.D., professor of internal medicine at Wake Forest Baptist and lead author of the studies.
Skeletal muscle tissue, which makes up 50 percent of the body, is easily accessible and biopsies of muscle are relatively harmless to the donor, so we think it may be an alternative source of neural-like cells that potentially could be used to treat brain or spinal cord injury, neurodegenerative disorders, brain tumors and other diseases, although more studies are needed.
In an earlier study, the Wake Forest Baptist team isolated neural precursor cells derived from skeletal muscle of adult transgenic mice (PLOS One, Feb.3, 2011).
In the current research, the team isolated neural precursor cells from in vitro adult skeletal muscle of various species including non-human primates and aging mice, and showed that these cells not only survived in the brain, but also migrated to the area of the brain where neural stem cells originate.
Another issue the researchers investigated was whether these neural-like cells would form tumors, a characteristic of many types of stem cells. To test this, the team injected the cells below the skin and in the brains of mice, and after one month, no tumors were found.
Right now, patients with glioblastomas or other brain tumors have very poor outcomes and relatively few treatment options, said Alexander Birbrair, a doctoral student in Delbonos lab and first author of these studies. Because our cells survived and migrated in the brain, we may be able to use them as drug-delivery vehicles in the future, not only for brain tumors but also for other central nervous system diseases.
In addition, the Wake Forest Baptist team is now conducting research to determine if these neural-like cells also have the capability to become functioning neurons in the central nervous system.
Co-authors of the studies are Tan Zhang, Ph.D., Zhong-Min Wang, M.S., Maria Laura Messi, M.S., Akiva Mintz, M.D., Ph.D., of Wake Forest Baptist, and Grigori N. Enikolopov, Ph.D., of Cold Spring Harbor Laboratory.
The present studies were supported by a PUSH grant from the Wake Forest Baptist Comprehensive Cancer Center to Drs. Akiva Mintz and Osvaldo Delbono; National Institute on Aging contract AG13934 and AG15820; the Claude D. Pepper Older Americans Independence Center of Wake Forest Baptist Medical Center grant P30-AG21332, and the National Institute of Aging grant R01AG040209.
Scientists at Wake Forest Baptist Medical Center have taken the first steps to create neural-like stem cells from muscle tissue in animals. Details of the work are published in two complementary studies published in the September online issues of the journals Experimental Cell Research and Stem Cell Research.
"Reversing brain degeneration and trauma lesions will depend on cell therapy, but we can't harvest neural stem cells from the brain or spinal cord without harming the donor," said Osvaldo Delbono, M.D., Ph.D., professor of internal medicine at Wake Forest Baptist and lead author of the studies.
"Skeletal muscle tissue, which makes up 50 percent of the body, is easily accessible and biopsies of muscle are relatively harmless to the donor, so we think it may be an alternative source of neural-like cells that potentially could be used to treat brain or spinal cord injury, neurodegenerative disorders, brain tumors and other diseases, although more studies are needed."
In an earlier study, the Wake Forest Baptist team isolated neural precursor cells derived from skeletal muscle of adult transgenic mice (PLOS One, Feb.3, 2011).
In the current research, the team isolated neural precursor cells from in vitro adult skeletal muscle of various species including non-human primates and aging mice, and showed that these cells not only survived in the brain, but also migrated to the area of the brain where neural stem cells originate.
Another issue the researchers investigated was whether these neural-like cells would form tumors, a characteristic of many types of stem cells. To test this, the team injected the cells below the skin and in the brains of mice, and after one month, no tumors were found.
"Right now, patients with glioblastomas or other brain tumors have very poor outcomes and relatively few treatment options," said Alexander Birbrair, a doctoral student in Delbono's lab and first author of these studies. "Because our cells survived and migrated in the brain, we may be able to use them as drug-delivery vehicles in the future, not only for brain tumors but also for other central nervous system diseases."
In addition, the Wake Forest Baptist team is now conducting research to determine if these neural-like cells also have the capability to become functioning neurons in the central nervous system.
Journal reference: PLoS ONE
Provided by Wake Forest University Baptist Medical Center
Originally posted here:
Stem cells from muscle tissue may hold key to cell therapies for neurodegenerative diseases
NEW YORK, Oct. 9, 2012 /PRNewswire/ --Today, The New York Stem Cell Foundation (NYSCF) will award a Japanese scientist with the NYSCF Robertson Prize for his extraordinary achievements in translational stem cell research.
This award will go to Kazutoshi Takahashi, PhD, Lecturer, Center for iPS Cell Research and Application (CiRA) at Kyoto University, for his vital contribution to induced pluripotent stem (iPS) cell derivation.
Dr. Takahashi was lead author on a series of landmark papers that described reprogramming adult cells into iPS cells, which were published while he was a postdoctoral researcher in Shinya Yamanaka's, MD, PhD, laboratory at Kyoto University.
Yesterday, judges in Stockholm announced that Dr. Yamanaka and Sir John Gurdon, DPhil, the Gurdon Institute, won the Nobel Prize in Physiology or Medicine for their stem cell research breakthroughs. Both scientists demonstrated that adult cells can be reprogrammed into pluripotent cells, cells that can become any cell type in the body.
The NYSCF Robertson prize will be presented at a ceremony in New York City by Susan L. Solomon, CEO of The New York Stem Cell Foundation, and Professor Peter J. Coffey, DPhil, the inaugural recipient of the NYSCF Robertson Prize in 2011, Executive Director of Translation at UC Santa Barbara's Center for Stem Cell Biology and Engineering, and Director of the London Project to Cure Blindness, University College London.
"Dr. Takahashi's path-breaking work truly has opened up the entire field of stem cell research," said Ms. Solomon. "In addition to his derivation of induced pluripotent stem cells, he focuses on improving this technique and other critical translational studies."
Dr. Takahashi's research group at Kyoto University was established in 2010 to focus on two areas of cellular reprogramming. Their first area of investigation is in the process of cellular reprogramming and the second area is evaluating iPS cell quality and differentiation potential.
"I congratulate Dr. Takahashi for his groundbreaking work, opening new avenues in the search for cures," said Julian H. Robertson, Jr. "The NYSCF Robertson Stem Cell Prize was created to recognize and support the work of young scientists like Dr. Takahashi, whose research offers enormous potential."
The jury that selected Dr. Takahashi in September consisted of Christine Mummery, PhD, Chair of the Department of Anatomy and Embryology at Leiden University Medical Center in the Netherlands; Lorenz Studer, MD, Director of the Sloan-Kettering Center for Stem Cell Biology; Irving Weissman, MD, Director of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford School of Medicine; and, Peter J. Coffey, DPhil.
The NYSCF Robertson prize is awarded annually to a young scientist in recognition of innovative and groundbreaking achievement, or body of work, that has significantly advanced human stem cell research toward clinical application. The terms of the prize require that the $200,000 stipend be used, at the recipients' discretion, to further support their research.
See more here:
Pioneering iPS Cell Scientist Kazutoshi Takahashi Receives NYSCF - Robertson Prize in Stem Cell Research
Two scientists who upended fundamental beliefs about biology by demonstrating that every cell in the body has the potential to grow into every other type of cell have won the Nobel Prize in physiology or medicine.
Sir John Gurdon and Dr. Shinya Yamanaka were honored Monday for "the discovery that mature cells can be reprogrammed" to return to a very early state of development, the Nobel committee said in its citation.
Their research is still years away from yielding a clear breakthrough in medical treatment. But the work has upended the study of intractable conditions including heart disease, diabetes and Alzheimer's by allowing scientists to grow disease-specific and even patient-specific cells for experimentation in the laboratory, experts said.
"It's nothing short of a revolution in how we think of a cell," said Dr. Deepak Srivastava, director of the Roddenberry Center for Stem Cell Biology and Medicine at the Gladstone Institutes in San Francisco, where Yamanaka works one week each month.
Gurdon, 79, performed his seminal work at Oxford University in the late 1950s and early 1960s a good deal of it before Yamanaka was born.
Working with frogs, he showed in 1962 that replacing the nucleus of an egg cell with the nucleus from a cell taken from a tadpole's intestine allowed the egg to develop into a fully functional clone of that tadpole.
The discovery shocked his colleagues in the field. At the time, it wasn't clear whether different types of body cells had different DNA or shared the same genetic instructions and just read them differently, Srivastava said. Gurdon's experiments indicated that cells did contain the same genetic code and that individual cells were capable of creating an entire animal and thus any of its component parts if properly manipulated.
It would take 34 years for Scottish researcher Ian Wilmut to clone Dolly the sheep, replicating the feat in a mammal and capturing the public's imagination.
Yamanaka's achievement was to give scientists an idea of how that cellular reprogramming gets done. When he began this line of work, he was highly criticized in Japan for undertaking such a difficult project.
The Japanese scientist who trained as an orthopedic surgeon before becoming a full-time researcher figured out that activating simple combinations of genes in a mouse skin cell could rewind that cell to an embryo-like state, allowing it to develop anew as any other type of cell in the body.
Go here to read the rest:
British, Japanese scientists share Nobel Prize for stem cell work